RxSight Inc

For the period ended Dec 31, 2024. Filed Feb 25, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 25, 2025

RXST$4.90+0.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

	Year Ended December 31,
	2024	2023	2022
Sales	$139,927	$89,077	$49,005
Cost of sales	40,984	35,312	27,677
Gross profit	98,943	53,765	21,328
Operating expenses:
Selling, general and administrative	101,434	74,799	58,665
Research and development	34,367	29,051	25,981
Total operating expenses	135,801	103,850	84,646
Loss from operations	(36,858)	(50,085)	(63,318)
Other income (expense), net:
Interest expense	(21)	(3,308)	(4,946)
Interest and other income	9,474	6,574	1,517
Loss on extinguishment of term loan	—	(1,769)	—
Loss before income taxes	(27,405)	(48,588)	(66,747)
Income tax expense	50	20	9
Net loss	$(27,455)	$(48,608)	$(66,756)
Other comprehensive (loss) income
Unrealized gain (loss) on short-term investments	180	83	(66)
Foreign currency translation (loss) gain	(9)	7	(9)
Total other comprehensive income (loss)	171	90	(75)
Comprehensive loss	$(27,284)	$(48,518)	$(66,831)
Net loss per share:
Basic and diluted	$(0.71)	$(1.41)	$(2.41)
Weighted-average shares used in computing net loss per share:
Attributable to common stock, basic and diluted	38,867,726	34,455,111	27,661,982

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.